ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Combination beta-lactamase inhibitors, carbapenems, and monobactams

Combination beta-lactamase inhibitors, carbapenems, and monobactams
Author:
Alyssa R Letourneau, MD, MPH
Section Editor:
David C Hooper, MD
Deputy Editor:
Keri K Hall, MD, MS
Literature review current through: Jan 2024.
This topic last updated: Nov 13, 2023.

INTRODUCTION — The spectrum of activity and pharmacology of combination beta-lactamase inhibitors, carbapenems, and monobactams will be reviewed here. The mechanisms of action and resistance and major adverse reactions of the beta-lactam antibiotics, issues related to penicillins, and cephalosporins are discussed separately. (See "Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects" and "Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins" and "Cephalosporins".)

BETA-LACTAMASE INHIBITOR COMBINATIONS — Clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, relebactam, and durlobactam are beta-lactamase inhibitors that have little intrinsic antibacterial activity but inhibit the activity of a number of plasmid-mediated beta-lactamases [1-3]. Avibactam, vaborbactam, and relebactam inhibit chromosomally mediated AmpC beta-lactamases, and none inhibit the class B metallo-carbapenemases, such as New Delhi metallo-beta-lactamase [2,4]. Combination of one of these agents with ampicillin, amoxicillin, piperacillin, ceftolozane, ceftazidime, meropenem, or imipenem-cilastatin results in antibiotics with an enhanced spectrum of activity against many, but not all, organisms containing plasmid-mediated beta-lactamases. The addition of avibactam to ceftazidime, vaborbactam to meropenem, and relebactam to imipenem-cilastatin results in enhanced activity against many, but not all, organisms producing carbapenemases. In addition, sulbactam and tazobactam inhibit the chromosomal beta-lactamase of many Bacteroides species, extending the spectrum of coverage of combinations with these compounds to include Bacteroides as well. Durlobactam, a novel diazabicyclooctane beta-lactamase inhibitor, was developed to treat Acinetobacter species (in combination with sulbactam) and inhibits Class A, C, and D beta-lactamases [3].

Dosing of combination beta-lactam beta-lactamase inhibitors is listed separately, and the dosing should be modified in the setting of renal dysfunction (table 1). For piperacillin-tazobactam, an extended infusion (eg, 3.375 g infused over four hours every eight hours) is an alternative to standard dosing; in particular, this strategy has been used for critically ill patients or for pathogens with elevated but susceptible-range minimum inhibitory concentrations (MICs). The benefits of extended infusion over standard dosing have been suggested by some studies but not all [5-7]. Overall, this dosing regimen is at least equivalent and may be superior to standard dosing in appropriate patient populations. (See "Prolonged infusions of beta-lactam antibiotics".)

Amoxicillin-clavulanate — Amoxicillin-clavulanate will inhibit most strains of oxacillin-susceptible Staphylococcus aureus and beta-lactamase producing Haemophilus influenzae in addition to the usual organisms inhibited by amoxicillin alone (see "Penicillin, antistaphylococcal penicillins, and broad-spectrum penicillins"). At the high drug concentrations achieved in urine, the combination is also active against certain beta-lactamase-producing Enterobacterales. Amoxicillin-clavulanate can be used as oral therapy for patients with otitis media, sinusitis, lower respiratory infections, bite wounds, and urinary tract infections [8], although there are no data that this combination is superior to other antibiotics (such as trimethoprim-sulfamethoxazole or the second or third generation oral cephalosporins). (See "Animal bites (dogs, cats, and other mammals): Evaluation and management".)

Ampicillin-sulbactam — Ampicillin-sulbactam is a parenteral formulation that expands the spectrum of ampicillin to include most strains of S. aureus and beta-lactamase producing H. influenzae, some Enterobacterales, and anaerobes (including Bacteroides fragilis). The sulbactam component of ampicillin-sulbactam has activity against many strains of Acinetobacter baumannii. Ampicillin-sulbactam has been used to treat patients with diabetic foot ulcers [9]. This combination has also been used for prophylaxis and therapy of intra-abdominal and pelvic infections instead of cefoxitin. Randomized, double-blind trials showed ampicillin-sulbactam to be equivalent to cefoxitin in prophylaxis for abdominal surgery and in the treatment of intra-abdominal and pelvic infections [10,11]. Increasing resistance worldwide to ampicillin-sulbactam in both Enterobacterales and B. fragilis in intra-abdominal infections, however, renders this drug combination less useful for these infections [12-14].

In some parts of the world, an oral prodrug of ampicillin-sulbactam, sultamicillin, is available in tablet form (sultamicillin tosylate) or powder for oral suspension [15]. Sultamicillin has a similar spectrum of activity to ampicillin-sulbactam and has been used for infections of the ear, sinus, throat, lower respiratory tract, urinary tract, female genital tract, skin, and soft tissues [16,17]. The adult dose ranges from 375 to 750 mg two to three times daily and warrants dose reduction in the setting of renal impairment.

Piperacillin-tazobactam — Piperacillin-tazobactam expands the spectrum of piperacillin to include beta-lactamase producing S. aureus, H. influenzae, Neisseria gonorrhoeae, some Enterobacterales, and anaerobes (including B. fragilis) [18]. This combination is generally not effective for piperacillin-resistant strains of Pseudomonas aeruginosa.

Piperacillin-tazobactam should be dosed at 4.5 g every six hours (for normal renal function) to treat susceptible P. aeruginosa infections. The increased dose allows for adequate drug concentrations to increase the time above the MIC, compared to the standard dose of 3.375 g every six hours. Prolonged-infusion dosing is discussed in detail elsewhere. (See "Prolonged infusions of beta-lactam antibiotics", section on 'Dosing'.)

Ceftolozane-tazobactam — Ceftolozane is a cephalosporin whose gram-negative activity is expanded by the addition of tazobactam. The combination has broad-spectrum in vitro activity against aerobic and facultative gram-negative bacilli, including P. aeruginosa and most extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. It has limited gram-positive activity against streptococci. Enterococcal and staphylococcal species are generally resistant. In clinical trials, clinical cure rates with ceftolozane-tazobactam were similar to those with levofloxacin for complicated urinary tract infections caused by levofloxacin-susceptible organisms and, when combined with metronidazole, were similar to those with meropenem for complicated intra-abdominal infections [19-21]. In these trials, ceftolozane-tazobactam also performed favorably against infections caused by ESBL-producing isolates [22]. It is also effective in treating carbapenem-resistant, ceftolozane-tazobactam susceptible P. aeruginosa pneumonia, as illustrated in a small multicenter, retrospective study [23]. Ceftolozane-tazobactam resulted in comparable clinical cure rates as meropenem for nosocomial pneumonia in mechanically ventilated patients [24]. Efficacy of ceftolozane-tazobactam may be attenuated in patients with renal impairment (estimated glomerular filtration rate [GFR] <50 mL/min).

Ceftazidime-avibactam — Avibactam is a novel broad-spectrum beta-lactamase inhibitor that has minimal antibacterial activity on its own. The addition of avibactam to ceftazidime extends the spectrum of activity to include most Enterobacterales (including those that produce AmpC beta-lactamase, ESBL, and some K. pneumoniae and OXA-type carbapenemases) as well as P. aeruginosa species with high MICs to ceftazidime alone. Ceftazidime-avibactam does not have activity against Acinetobacter species or organisms that produce metallo-beta-lactamases and is less active against anaerobes than other beta lactam-beta-lactamase combinations [25]. In trials, the microbiological efficacy and clinical cure rates with ceftazidime-avibactam were similar to those with meropenem for nosocomial pneumonia [26], imipenem-cilastatin for complicated urinary tract infection, and, when combined with metronidazole, overall similar to those with meropenem for complicated intra-abdominal infections [27-29]. The microbiological and clinical efficacy of ceftazidime-avibactam against isolates that were not ceftazidime susceptible also compared favorably with that of the carbapenem comparator.

Meropenem-vaborbactam — Vaborbactam is a novel broad-spectrum beta-lactamase inhibitor that potently inhibits class A carbapenemases (including K. pneumoniae carbapenemases [KPC]). It is not active against class B or D carbapenemases (ie, metallo-beta-lactamases and OXA-type enzymes). The addition of vaborbactam to meropenem reduces the MICs of meropenem for class A carbapenemase-producing Enterobacterales to wild-type MIC levels [30,31]. Meropenem-vaborbactam was comparable to piperacillin-tazobactam in a trial of patients with complicated urinary tract infection [32]. In a small open-label, randomized controlled trial of patients with carbapenem-resistant Enterobacterales (CRE) infections, including bacteremia, hospital-acquired pneumonia including ventilator-associated pneumonia, complicated intra-abdominal infections, and complicated urinary tract infection/pyelonephritis, meropenem-vaborbactam was associated with increased clinical cure, decreased mortality, and decreased nephrotoxicity compared to the best-available therapy [33]. The main role of this agent is for treatment of KPC-producing Enterobacterales.

Vaborbactam does not enhance the clinical activity of meropenem against carbapenem-resistant P. aeruginosa or Acinetobacter spp.

Imipenem-cilastatin-relebactam — Relebactam is a broad-spectrum beta-lactamase inhibitor that inhibits class A carbapenemases (including KPC). It is not active against class B or D carbapenemases (ie, metallo-beta-lactamases and OXA-type enzymes). The addition of relebactam to imipenem-cilastatin improves the activity against most species of Enterobacterales (reduces the MIC by 2- to 128-fold) and against some imipenem-nonsusceptible P. aeruginosa (reduces the MIC eightfold) [34-36]. In clinical trials of patients with complicated urinary tract infections and intraabdominal infections, the efficacy and safety of imipenem-cilastatin-relebactam were comparable with those of imipenem-cilastatin [37,38]. The main role of this agent is for treatment of KPC-producing Enterobacterales, but clinical data evaluating imipenem-cilastatin-relebactam for such infections are limited [39].

Relebactam does not enhance the clinical activity of imipenem-cilastatin against Acinetobacter species or Stenotrophomonas maltophilia.

Sulbactam-durlobactam — Durlobactam, a novel diazabicyclooctane (non-beta lactam) beta-lactamase inhibitor, was developed to treat Acinetobacter species in combination with sulbactam and inhibits Class A, C, and D beta-lactamases [3]. In vitro, sulbactam-durlobactam is highly active against Acinetobacter baumannii-calcoaceticus complex [3]. In a large study of 5032 isolates, addition of durlobactam lowered the MIC90 of sulbactam by 32-fold [40]. In the phase 3 ATTACK trial, sulbactam-durlobactam was found to be noninferior for 28-day all-cause mortality compared to colistin, both drugs in combination with imipenem-cilastatin, for treating serious Acinetobacter species infections [41]. It also had a favorable safety profile with decreased incidence of nephrotoxicity compared to colistin. Sulbactam-durlobactam has been approved by the US Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex, but it is not yet available in all centers.

CARBAPENEMS — Carbapenems are generally resistant to cleavage by most plasmid and chromosomal beta-lactamases and have a very broad spectrum of activity encompassing [42,43]:

●Gram-negative organisms (including beta-lactamase producing H. influenzae and N. gonorrhoeae, the Enterobacterales, and P. aeruginosa), including those that produce extended-spectrum beta-lactamases

●Anaerobes (including B. fragilis)

●Gram-positive organisms (including Enterococcus faecalis and Listeria)

Carbapenems are not generally active against S. maltophilia (which has a carbapenem-hydrolyzing chromosomal beta-lactamase), Burkholderia cepacia, Enterococcus faecium, oxacillin-resistant staphylococci, or JK diphtheroids.

Although initial isolates of P. aeruginosa are usually susceptible to the carbapenems, resistance may emerge on therapy when these drugs are used as a single agent. Evidence suggests that carbapenems do not traverse the outer membrane of P. aeruginosa through the normal porin channel used by the other beta-lactams but rather through a different channel [44]. Carbapenem-resistant strains of P. aeruginosa arising on therapy generally have altered permeability to these drugs and specific changes in their outer membrane proteins or increased expression of efflux pumps; such strains are generally not cross-resistant to other beta-lactams nor do they produce increased or novel beta-lactamase activity.

Carbapenem-hydrolyzing beta-lactamases have been increasingly isolated from gram-negative organisms and may limit therapy with these agents in these circumstances. (See "Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects" and "Carbapenem-resistant E. coli, K. pneumoniae, and other Enterobacterales (CRE)".)

All carbapenems should be dose-reduced in the setting of renal dysfunction (table 1).

Imipenem-cilastatin — Imipenem-cilastatin is inactivated in the proximal renal tubule by the normal human enzyme renal dehydropeptidase I, with resultant low urinary levels of active drug and necrosis of the proximal tubule in the rabbit model. Such cleavage of imipenem-cilastatin is prevented by coadministration of cilastatin, a specific inhibitor of this dehydropeptidase. Imipenem-cilastatin (500 mg IV every six hours with normal renal function) is available for clinical use. The dosing of imipenem-cilastatin should be carefully titrated; patients with creatinine clearance <15 mL/min should generally not receive imipenem-cilastatin unless hemodialysis is ongoing or will start within 48 hours.

Imipenem-cilastatin therapy has been associated with central nervous system (CNS) toxicity, including change in mental state, myoclonus, and seizures [45]. In a meta-analysis of over 100 studies that compared imipenem-cilastatin to a non-carbapenem antibiotic, imipenem-cilastatin use was associated with an excess of 4 seizures per 1000 patients treated [46]. CNS toxicity with imipenem-cilastatin is especially evident in patients with underlying CNS disease or impaired renal function. Imipenem-cilastatin should not be used for the therapy of meningitis.

Meropenem — Meropenem has a spectrum of activity similar to that of imipenem-cilastatin [47]. Unlike imipenem-cilastatin, meropenem is stable to human renal dehydropeptidase I and can be administered without cilastatin. Meropenem may have a slightly lower risk of producing seizures than imipenem-cilastatin, but that decrease was not seen in direct head-to-head comparisons that were limited by small sample size [46]. Meropenem is useful for the treatment of bacterial meningitis (in pediatric patients >3 months old) and intra-abdominal infection [48,49].

Ertapenem — Ertapenem has a narrower spectrum of activity than imipenem-cilastatin or meropenem. It is active against most Enterobacterales and anaerobes but less active than the other carbapenems for P. aeruginosa, Acinetobacter, and gram-positive bacteria, particularly enterococci and penicillin-resistant pneumococci. The major benefit of ertapenem over other carbapenems is that it has a long half-life and can be administered once daily. Unlike meropenem, there are insufficient data to support the use of ertapenem for the therapy of meningitis.

Doripenem — Doripenem has demonstrated clinical efficacy in the treatment of complicated urinary tract and intra-abdominal infections [50,51]. It has a similar overall spectrum of activity as that of meropenem but has somewhat greater in vitro activity against P. aeruginosa [52,53].

In 2014, the US Food and Drug Administration (FDA) approved revisions to the doripenem label warning clinicians about increased mortality rates in patients with ventilator-associated bacterial pneumonia who received doripenem rather than imipenem-cilastatin, based on results of a randomized trial that was stopped early due to safety concerns [54]. In the trial, 28-day all-cause mortality was higher and clinical response rates were lower with doripenem compared with imipenem-cilastatin, although different dosing regimens and use of adjunctive aminoglycosides may have influenced these results [55]. (See "Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Gram-negative pathogens'.)

Further clinical trials are required to establish the efficacy and safety of doripenem in the setting of bacteremia and other severe infections.

MONOBACTAMS (AZTREONAM) — Aztreonam is a monocyclic beta-lactam antibiotic with good in vitro activity against the majority of gram-negative aerobic and facultative bacteria, including the Enterobacterales and P. aeruginosa [43,56]. It has virtually no activity against gram-positive organisms or anaerobes; the majority of strains of Acinetobacter and S. maltophilia are resistant, and resistant strains of P. aeruginosa frequently emerge during therapy with aztreonam alone. The spectrum of activity of aztreonam is similar to that of the aminoglycosides. It is, however, less reliable therapy than aminoglycosides for the non-enteric gram-negative bacilli, such as Acinetobacter, P. aeruginosa, and S. maltophilia.

Aztreonam is distinctive in that it is not degraded by the class B metallo-beta-lactamases, such as New Delhi metallo-beta-lactamase. (See "Carbapenem-resistant E. coli, K. pneumoniae, and other Enterobacterales (CRE)", section on 'Classifications and geographic distribution'.)

Data support the absence of cross-allergenicity between aztreonam and other beta-lactam antibiotics [57]. Patients with ceftazidime allergy, however, may be allergic to aztreonam because of a shared side chain. The clinical situation in which aztreonam is most useful is in place of an extended-spectrum penicillin or cephalosporin when these are indicated but cannot be used because of severe allergy. Aztreonam is the only monobactam currently marketed. Dose reductions are recommended in the setting of renal dysfunction (table 1).

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical terminology.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

●Basics topic (see "Patient education: Carbapenem-resistant enterobacterales (The Basics)")

SUMMARY AND RECOMMENDATIONS

●Combination beta-lactamase inhibitors – Clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, relebactam, and durlobactam are beta-lactamase inhibitors that have little intrinsic antibacterial activity but inhibit the activity of a number of plasmid-mediated beta-lactamases. Combination of one of these agents with ampicillin, amoxicillin, piperacillin, ceftolozane, or ceftazidime results in antibiotics with an enhanced spectrum of activity against many, but not all, organisms containing plasmid-mediated beta-lactamases. The addition of avibactam to ceftazidime, vaborbactam to meropenem, and relebactam to imipenem-cilastatin results in enhanced activity against many, but not all, organisms producing carbapenemases. The sulbactam component of ampicillin-sulbactam has activity against Acinetobacter, as does the new combination sulbactam-durlobactam. (See 'Beta-lactamase inhibitor combinations' above.)

●Carbapenems – Carbapenems have a broad spectrum of activity against gram-negative organisms (including those that produce extended spectrum beta-lactamases), anaerobes (including Bacteroides fragilis), and gram-positive organisms (including Enterococcus faecalis and Listeria). When carbapenems are used as a single agent against initially susceptible isolates of Pseudomonas aeruginosa, resistance may emerge during therapy. (See 'Carbapenems' above.)

●Aztreonam – Aztreonam is a monocyclic beta-lactam with good in vitro activity against the majority of gram-negative aerobic and facultative bacteria, including the Enterobacterales and P. aeruginosa, but virtually no activity against gram-positive organisms or anaerobes. However, when used alone for therapy of P. aeruginosa infection, resistance may emerge. Aztreonam has minimal cross-allergenicity with other beta-lactams with the exception of ceftazidime. (See 'Monobactams (aztreonam)' above.)

●Dosing – The dosing of these novel beta-lactams and dose modifications in patients with renal dysfunction (table 1) are important considerations in prescribing these drugs.

  1. Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. Infect Dis Clin North Am 2000; 14:409.
  2. Yahav D, Giske CG, Grāmatniece A, et al. New β-Lactam-β-Lactamase Inhibitor Combinations. Clin Microbiol Rev 2020; 34.
  3. Papp-Wallace KM, McLeod SM, Miller AA. Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species. Clin Infect Dis 2023; 76:S194.
  4. Sensakovic JW, Smith LG. Beta-lactamase inhibitor combinations. Med Clin North Am 1995; 79:695.
  5. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357.
  6. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56:272.
  7. Monti G, Bradic N, Marzaroli M, et al. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA 2023; 330:141.
  8. Calver AD, Walsh NS, Quinn PF, et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group. Clin Infect Dis 1997; 24:570.
  9. McKinnon PS, Paladino JA, Grayson ML, et al. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997; 24:57.
  10. Messick CR, Mamdani M, McNicholl IR, et al. Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections. Pharmacotherapy 1998; 18:175.
  11. Paladino JA, Rainstein MA, Serrianne DJ, et al. Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery. Pharmacotherapy 1994; 14:734.
  12. Liu CY, Huang YT, Liao CH, et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008; 52:3161.
  13. Hoban DJ, Bouchillon SK, Hawser SP, et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54:3031.
  14. Hsueh PR, Badal RE, Hawser SP, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents 2010; 36:408.
  15. Unasyn (oral). International prescribing information. New York, NY: Pfizer Inc; 2012.
  16. Friedel HA, Campoli-Richards DM, Goa KL. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1989; 37:491.
  17. Lode H. Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. Int J Antimicrob Agents 2001; 18:199.
  18. Sanders WE Jr, Sanders CC. Piperacillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996; 22:107.
  19. Zerbaxa (ceftolozane/tazobactam). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on January 08, 2015).
  20. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949.
  21. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462.
  22. Popejoy MW, Paterson DL, Cloutier D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother 2017; 72:268.
  23. Munita JM, Aitken SL, Miller WR, et al. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis 2017.
  24. Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2019; 19:1299.
  25. Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 2013; 73:159.
  26. Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 2018; 18:285.
  27. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis 2016; 62:1380.
  28. Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012; 28:1921.
  29. Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661.
  30. Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61.
  31. Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61.
  32. Kaye KS, Bhowmick T, Metallidis S, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018; 319:788.
  33. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018; 7:439.
  34. Schmidt-Malan SM, Mishra AJ, Mushtaq A, et al. In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli. Antimicrob Agents Chemother 2018; 62.
  35. Young K, Painter RE, Raghoobar SL, et al. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol 2019; 19:150.
  36. Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs 2018; 78:65.
  37. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother 2017; 72:2616.
  38. Lucasti C, Vasile L, Sandesc D, et al. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. Antimicrob Agents Chemother 2016; 60:6234.
  39. Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis 2020; 70:1799.
  40. Karlowsky JA, Hackel MA, McLeod SM, Miller AA. In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021. Antimicrob Agents Chemother 2022; 66:e0078122.
  41. Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 2023; 23:1072.
  42. Norrby SR. Carbapenems. Med Clin North Am 1995; 79:745.
  43. Asbel LE, Levison ME. Cephalosporins, carbapenems, and monobactams. Infect Dis Clin North Am 2000; 14:435.
  44. Huang H, Hancock RE. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. J Bacteriol 1993; 175:7793.
  45. Calandra G, Lydick E, Carrigan J, et al. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84:911.
  46. Cannon JP, Lee TA, Clark NM, et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014; 69:2043.
  47. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995; 21:86.
  48. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21:544.
  49. Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg 1997; 174:284.
  50. Naber KG, Llorens L, Kaniga K, et al. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009; 53:3782.
  51. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30:868.
  52. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67:1027.
  53. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009; 49:291.
  54. US Food and Drug Administration. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm (Accessed on March 10, 2014).
  55. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218.
  56. Johnson DH, Cunha BA. Aztreonam. Med Clin North Am 1995; 79:733.
  57. Kishiyama JL, Adelman DC. The cross-reactivity and immunology of beta-lactam antibiotics. Drug Saf 1994; 10:318.
Topic 482 Version 34.0

References

1 : Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations.

2 : Newβ-Lactam-β-Lactamase Inhibitor Combinations.

3 : Durlobactam, a Broad-Spectrum Serineβ-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.

4 : Beta-lactamase inhibitor combinations.

5 : Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

6 : Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.

7 : Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.

8 : Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Lower Respiratory Tract Infection Collaborative Study Group.

9 : Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.

10 : Pharmacoeconomic analysis of ampicillin-sulbactam versus cefoxitin in the treatment of intraabdominal infections.

11 : Ampicillin-sulbactam versus cefoxitin for prophylaxis in high-risk patients undergoing abdominal surgery.

12 : Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

13 : Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

14 : Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

15 : Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).

16 : Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

17 : Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections.

18 : Piperacillin/tazobactam: a critical review of the evolving clinical literature.

19 : Piperacillin/tazobactam: a critical review of the evolving clinical literature.

20 : Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

21 : Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

22 : Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.

23 : Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.

24 : Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.

25 : Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.

26 : Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.

27 : Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.

28 : Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.

29 : Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.

30 : Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.

31 : Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.

32 : Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.

33 : Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

34 : In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.

35 : In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.

36 : Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

37 : Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

38 : Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.

39 : RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

40 : In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021.

41 : Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).

42 : Carbapenems.

43 : Cephalosporins, carbapenems, and monobactams.

44 : Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa.

45 : Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.

46 : The risk of seizures among the carbapenems: a meta-analysis.

47 : A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.

48 : Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial.

49 : Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections.

50 : Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis.

51 : Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.

52 : Comparative review of the carbapenems.

53 : Doripenem.

54 : Doripenem.

55 : A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.

56 : Aztreonam.

57 : The cross-reactivity and immunology of beta-lactam antibiotics.

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟